Arcadia Biosciences (RKDA) Current Deferred Revenue (2014 - 2021)

Arcadia Biosciences has reported Current Deferred Revenue for 8 years, with the latest figure at $63000.0 in Q2 2021.

• For the quarter ending Q2 2021, Current Deferred Revenue changed N/A year-over-year to $63000.0; the trailing twelve-month figure through Jun 2021 stood at $63000.0 (changed N/A YoY), and the FY2020 full-year result was $8000.0, down 80.95% from the prior year.
• Current Deferred Revenue for Q2 2021 stood at $63000.0, roughly flat from $63000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $1.0 million in Q4 2017, with the low at $8000.0 in Q4 2020.
• Historically, Current Deferred Revenue has averaged $310875.0 across 5 years, with a median of $88000.0 in 2018.
• Annual changes were most pronounced in 2019 — Current Deferred Revenue tumbled 96.81% — and 2021, when it jumped 270.59%.
• Arcadia Biosciences' Current Deferred Revenue stood at $1.0 million in 2017, then sank by 90.4% to $96000.0 in 2018, then tumbled by 56.25% to $42000.0 in 2019, then sank by 80.95% to $8000.0 in 2020, then soared by 687.5% to $63000.0 in 2021.
• The last three Current Deferred Revenue figures came in at $63000.0 (Q2 2021), $63000.0 (Q1 2021), and $8000.0 (Q4 2020), per Business Quant data.